Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities

[1]  Daosheng Huang,et al.  Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors , 2021, Science Translational Medicine.

[2]  B. Cao,et al.  Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer , 2021, Oncogene.

[3]  James M. McFarland,et al.  Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition , 2021, Nature.

[4]  G. Goodall,et al.  Phosphorylation of PKCδ by FER tips the balance from EGFR degradation to recycling , 2021, The Journal of cell biology.

[5]  Jing Wang,et al.  Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  M. Huang,et al.  Selective exosome exclusion of miR-375 by glioma cells promotes glioma progression by activating the CTGF-EGFR pathway , 2020, Journal of experimental & clinical cancer research : CR.

[7]  Ashutosh Kumar Singh,et al.  Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK directed activation of NF-κB , 2020, Oncogene.

[8]  Ying Liang,et al.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. , 2020, Cancer cell.

[9]  Yi-Wen Chang,et al.  STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis , 2020, Oncogene.

[10]  R. Birge,et al.  Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity , 2020, Cancer Research.

[11]  M. Vasconcelos,et al.  Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine. , 2020, Cancer letters.

[12]  Yang Zhang,et al.  KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway , 2020, Cell Death & Differentiation.

[13]  M. Sos,et al.  The next tier of EGFR resistance mutations in lung cancer , 2020, Oncogene.

[14]  Ying Cheng,et al.  Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal circulating tumor DNA Monitoring in Advanced EGFR-mutant Lung Adenocarcinoma under Gefitinib Treatment. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  E. Dmitrovsky,et al.  A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components , 2020, Science Translational Medicine.

[16]  Maohui Luo,et al.  Multi-organ proteomic landscape of COVID-19 autopsies , 2020, Cell.

[17]  S. Chiou,et al.  Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination , 2020, Cancer Research.

[18]  Jian Ma,et al.  Interaction of non-coding RNAs and Hippo signaling: Implications for tumorigenesis. , 2020, Cancer letters.

[19]  Joshua D. Campbell,et al.  Whole genome doubling confers unique genetic vulnerabilities on tumor cells , 2020, Nature.

[20]  E. Jho,et al.  MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis , 2020, Proceedings of the National Academy of Sciences.

[21]  M. Hung,et al.  ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. , 2020, Cancer cell.

[22]  Oliver Fiehn,et al.  A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors , 2020, Cell.

[23]  A. Gemma,et al.  Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Dutt,et al.  Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Pe’er,et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.

[26]  Henry W. Long,et al.  Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. , 2020, Cancer cell.

[27]  M. Okada,et al.  Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma , 2019, Cell Communication and Signaling.

[28]  M. Tschan,et al.  Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma , 2019, Cell Death & Disease.

[29]  D. Pe’er,et al.  Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[31]  Hongzhuan Chen,et al.  Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer , 2019, Molecular Cancer Therapeutics.

[32]  K. Guan,et al.  The Hippo Pathway: Biology and Pathophysiology. , 2019, Annual review of biochemistry.

[33]  R. Rosell,et al.  AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy , 2019, Nature Communications.

[34]  Emanuel J. V. Gonçalves,et al.  Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening , 2019, Nature Communications.

[35]  J. Ahn,et al.  Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  S. Yano,et al.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.

[37]  N. Yang,et al.  NTRK1 is a positive regulator of YAP oncogenic function , 2018, Oncogene.

[38]  Kwok-Kin Wong,et al.  Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. , 2018, Cancer cell.

[39]  Sourav Bandyopadhyay,et al.  Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer , 2018, Nature Medicine.

[40]  S. Bicciato,et al.  Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 , 2018, Nature Medicine.

[41]  Ying Cheng,et al.  Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. , 2018, The Lancet. Respiratory medicine.

[42]  H. Hondermarck,et al.  The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung , 2018, Scientific Reports.

[43]  Sarah J. Kurley,et al.  Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer , 2018, Nature Medicine.

[44]  M. Ladanyi,et al.  Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance , 2018, Clinical Cancer Research.

[45]  S. Cascinu,et al.  Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. , 2018, Critical reviews in oncology/hematology.

[46]  M. Okada,et al.  Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis , 2018, EBioMedicine.

[47]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[48]  C. Zahnow,et al.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.

[49]  J. Werner,et al.  β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. , 2018, Cancer cell.

[50]  Edward S. Kim,et al.  Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers , 2017, Science Translational Medicine.

[51]  W. Park,et al.  Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts , 2017, Cancer science.

[52]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[53]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[54]  H. Ditzel,et al.  Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer , 2017, Nature Communications.

[55]  Amanda R. Kulick,et al.  SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. , 2017, Cancer research.

[56]  Xianming Deng,et al.  Hippo Signaling Suppresses Cell Ploidy and Tumorigenesis through Skp2. , 2017, Cancer cell.

[57]  R. Rosell,et al.  Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC) , 2017, Oncotarget.

[58]  M. Kirschner,et al.  Hippo pathway mediates resistance to cytotoxic drugs , 2017, Proceedings of the National Academy of Sciences.

[59]  Zhike Lu,et al.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. , 2017, Cancer cell.

[60]  H. Ditzel,et al.  Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC , 2017, Journal of the National Cancer Institute.

[61]  Yan Liang,et al.  Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung cancer proliferation , 2016, Scientific Reports.

[62]  Xiaoxiao Sun,et al.  Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment , 2016, Molecular Cancer Therapeutics.

[63]  L. Richard,et al.  TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells , 2016, Oncotarget.

[64]  N. Tonks,et al.  HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer , 2016, Genes & development.

[65]  Tzu-chin Wu,et al.  PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation , 2016, Clinical Cancer Research.

[66]  J. Arbiser,et al.  Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis , 2016, Clinical Cancer Research.

[67]  Suyun Huang,et al.  HGF/Met and FOXM1 Form a Positive Feedback Loop and Render Pancreatic Cancer Cells Resistance to Met Inhibition and Aggressive Phenotypes , 2015, Oncogene.

[68]  P. Jänne,et al.  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. , 2015, Cancer discovery.

[69]  Angela Tam,et al.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. , 2015, Cancer cell.

[70]  John T. Chang,et al.  A gp130–Src–YAP module links inflammation to epithelial regeneration , 2015, Nature.

[71]  Naveid A Ali,et al.  The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking , 2015, Science Signaling.

[72]  T. Golub,et al.  Genetic modifiers of EGFR dependence in non-small cell lung cancer , 2014, Proceedings of the National Academy of Sciences.

[73]  E. Haura,et al.  Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[74]  G. Kéri,et al.  Connective tissue growth factor is a new ligand of epidermal growth factor receptor. , 2013, Journal of molecular cell biology.

[75]  A. Ullrich,et al.  HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors , 2013, Oncogene.

[76]  Li Zhang,et al.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. , 2013, The Lancet. Oncology.

[77]  R. Rosell.  Mediating resistance in oncogene-driven cancers. , 2013, The New England journal of medicine.

[78]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[79]  Peijing Zhang,et al.  LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker , 2012, Nature Medicine.

[80]  P. Bunn,et al.  Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. , 2012, Cancer research.

[81]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[82]  B. Halmos,et al.  MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. , 2011, Cancer research.

[83]  A. Stemmer-Rachamimov,et al.  A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. , 2011, Cancer cell.

[84]  H. Hieronymus,et al.  FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.

[85]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[86]  M. Rao,et al.  Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase , 2011, Cell.

[87]  M. Meyerson,et al.  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.

[88]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[89]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[90]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[91]  An Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. , 2018, Cancer discovery.

[92]  D. Takai,et al.  FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer. , 2013, International journal of clinical and experimental pathology.